Afficher la notice abrégée

Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan

dc.rights.licenseopenen_US
dc.contributor.authorAUZANNEAU, C.
dc.contributor.authorBACQ, D.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorBLONS, H.
dc.contributor.authorBOLAND, A.
dc.contributor.authorBOUCHEIX, M.
dc.contributor.authorBOURDON, A.
dc.contributor.authorCHOLLET, E.
dc.contributor.authorCHOMIENNE, C.
dc.contributor.authorDELEUZE, J. F.
dc.contributor.authorDELMAS, C.
dc.contributor.authorDINART, D.
dc.contributor.authorESPÉROU, H.
dc.contributor.authorGEILLON, F.
dc.contributor.authorGENESTE, D.
dc.contributor.authorITALIANO, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorJEAN, Delphine
dc.contributor.authorKHALIFA, E.
dc.contributor.authorLAIZET, Y.
dc.contributor.authorLAURENT-PUIG, P.
dc.contributor.authorLETHIMONNIER, F.
dc.contributor.authorLÉVY-MARCHAL, C.
dc.contributor.authorLUCCHESI, C.
dc.contributor.authorMALLE, C.
dc.contributor.authorMANCINI, P.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN-PELISSIER, Simone
dc.contributor.authorMEYER, V.
dc.contributor.authorMARIE-ANGE, P.
dc.contributor.authorPERKINS, G.
dc.contributor.authorSELLAN-ALBERT, S.
dc.contributor.authorSOUBEYRAN, I.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWALLET, Cedrick
dc.date.accessioned2021-01-26T10:51:03Z
dc.date.available2021-01-26T10:51:03Z
dc.date.issued2020
dc.identifier.issn2059-7029 (Electronic) 2059-7029 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26007
dc.description.abstractEnBackground Whole exome sequencing and RNA sequencing (WES/RNASeq) should now be implemented in the clinical practice in order to increase access to optimal care for cancer patients. Providing results to Tumour Boards in a relevant time frame—that is, compatible with the clinical pathway—is crucial. Assessing the feasibility of this implementation in the French care system is the primary objective of the Multipli study, as one of the four pilot projects of the national France Genomic Medicine 2025 (FGM 2025) plan. The Multipli study encompasses two innovative trials which will be driven in around 2400 patients suffering from a soft-tissue sarcoma (Multisarc) or a metastatic colorectal carcinoma (Acompli). Methods Prior to launching the FGM 2025 cancer pilot study itself, the performance of the Multipli genomic workflow has been evaluated through each step, from the samples collection to the Molecular Tumour Board (MTB) report. Two Multipli-assigned INCa-labelled molecular genetics centres, the CEA-CNRGH sequencing platform and the Institut Bergonié’s Bioinformatics Platform were involved in a multicentric study. The duration of each step of the genomic workflow was monitored and bottlenecks were identified. Results Thirty barriers which could affect the quality of the samples, sequencing results and the duration of each step of the genomic pathway were identified and mastered. The global turnaround time from the sample reception to the MTB report was of 44 calendar days. Conclusion Our results demonstrate the feasibility of tumour genomic analysis by WES/RNASeq within a time frame compatible with the current cancer patient care. Lessons learnt from the Multipli WES/RNASeq Platforms Workflow Study will constitute guidelines for the forthcoming Multipli study and more broadly for the future clinical routine practice in the first two France Genomic Medicine 2025 platforms.
dc.language.isoENen_US
dc.subjectEPICENE
dc.title.enFeasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan
dc.title.alternativeESMO Openen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/esmoopen-2020-000744en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32713836en_US
bordeaux.journalEuropean Society for Medical Oncologyen_US
bordeaux.volume5en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03121260
hal.version1
hal.date.transferred2021-01-26T10:51:09Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Society%20for%20Medical%20Oncology&rft.date=2020&rft.volume=5&rft.issue=4&rft.eissn=2059-7029%20(Electronic)%202059-7029%20(Linking)&rft.issn=2059-7029%20(Electronic)%202059-7029%20(Linking)&rft.au=AUZANNEAU,%20C.&BACQ,%20D.&BELLERA,%20Carine&BLONS,%20H.&BOLAND,%20A.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée